v117957
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01900795)
Timeline
Indications
Mechanism of action
- Nociceptin receptorACTIVATOR
OPRL1 activator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1nc2ccccc2n([C@@H]2C[C@H]3CCC[C@@H](C2)N3C2C[C@H]3CCC[C@@H](C2)C3)c1=O- Mol. weight
- 435.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095040 ↗
Also known as
- v117957
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06545916 | Phase 2 | Oct 14, 2024 | Purdue Pharmaceuticals |
| NCT06545929 | Phase 2 | Sep 30, 2024 | Purdue Pharmaceuticals |
| NCT06024642 | Phase 1 | Jun 30, 2022 | Purdue Pharmaceuticals |
| NCT06285214 | Phase 1 | May 26, 2022 | Purdue Pharmaceuticals |
| NCT04035200 | Phase 2 | Aug 31, 2019 | Purdue Pharmaceuticals |
| NCT01900795 | Phase 2 | Jul 1, 2013 | Purdue Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Purdue Pharmaceuticals | For profit | 6 | 6 | 2 | 2013 |
1 organizations
Page 1 / 1